A Clinical Study to Assess the Effects of a Stannous Fluoride Dentifrice on Plaque and Gingivitis
Completed · Phase 4
Conditions studied: Gingivitis
In brief
The objective of this clinical study is to assess the effects of a 0.454% stannous fluoride dentifrice on gingivitis and plaque after 3 months when compared to a negative control.
Key facts
- Study ID
- NCT03936556
- Run by
- Procter and Gamble
- People needed
- 84
- Starts
- 2018-02-25
- Expected to finish
- 2018-06-03
- Last updated by the study team
- 2019-12-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Be at least 18 years of age;
- Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
- Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;
- Have at least 16 gradable teeth;
- Agree to return for scheduled visits and follow the study procedures;
- Agree to refrain from use of any non-study oral hygiene products for the duration of the study;
- Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study;
You may not qualify if…
- Having taken antibiotic, anti-inflammatory, or anti-coagulant medications within 4 weeks of the Baseline Visit;
- Have any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;
- Removable oral appliances;
- Fixed facial or lingual orthodontic appliances;
- Self-reported pregnancy or lactation;
- Any diseases or condition that might interfere with the safe participation in the study; and
- Inability to undergo study procedures.
Where it is running
- University Health Resources Group — Whittier, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.